All In Biotech

Drug Trial Radar · NCT06132126

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Nov 17, 2023

Primary completion

Jun 28, 2024

Study completion Jun 28, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.

Conditions

  • Healthy
  • Type 2 Diabetes Mellitus

Interventions

  • LY3938577Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

  • Insulin degludecDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationTime frame: Baseline up to 16 days
  2. Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationTime frame: Baseline up to 44 days
  3. Part A: Incidence of HypoglycemiaTime frame: Baseline up to 16 days
  4. Part B: Incidence of HypoglycemiaTime frame: Baseline up to 44 days
  5. Part A: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to 16 days
  6. Part B: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to 44 days
  7. Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to 16 days
  8. Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to 44 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel ACT

    Anaheim, California

  • Qps-Mra, Llc

    Miami, Florida

  • Labcorp CRU

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.